Alphabet Inc.

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 1, 2025), Alphabet Inc. reported 36 stock positions worth $2.1 billion. Its top holding was Ast Spacemobile (ASTS) at 19.6% of the portfolio, followed by Arm Holdings PLC-ADR (ARM, 14.9%) and Freshworks Class A (FRSH, 11.3%). Compared with Q1 2025, it sold out of 4 and reduced 1. The biggest sale was an exit from CrowdStrike Class A (CRWD).

Most Recent 13F
Q2 2026
Location
Mountain View, CA
CIK
0001652044
Portfolio Value
$2.1B (Q2 2025)
SEC Filing
0001652044-25-000063 ↗ filed Aug 1, 2025

Holdings Value

0$20.0B$40.0B$60.0B$80.0B$100.0B Q1 2024: $2.5B Q1 2024 Q2 2024: $2.0B Q2 2024 Q3 2024: $1.8B Q3 2024 Q4 2024: $1.7B Q4 2024 Q1 2025: $1.6B Q1 2025 Q2 2025: $2.1B $2.1B Q2 2025 Q3 2025: $2.4B Q3 2025 Q4 2025: $2.6B Q4 2025 Q1 2026: $4.0B Q1 2026 Q2 2026: $99.1B Q2 2026

Holdings 36 stocks · $2.1B
ASTS Ast Spacemobile Inc. 19.57% 8,943,486 $417.9M No change
ARM Arm Holdings PLC-ADR 14.85% 1,960,784 $317.1M No change
FRSH Freshworks Inc. Class A 11.32% 16,206,643 $241.6M No change
PL Planet Labs PBC 9.13% 31,942,641 $194.9M No change
RVMD Revolution Medicines Inc. 7.12% 4,133,277 $152.1M No change
MTSR Metsera Inc. 6.61% 4,961,744 $141.2M No change
VERV Verve Therapeutics Inc. 6.40% 12,168,489 $136.7M Reduce -1.5%
GTLB Gitlab Inc. Class A 5.76% 2,724,712 $122.9M No change
TEM Tempus AI Inc. Class A 4.62% 1,551,102 $98.6M No change
DXCM Dexcom Inc. 4.24% 1,036,937 $90.5M No change
PATH Uipath Inc. Class A 4.22% 7,034,337 $90.0M No change
PRME Prime Medicine Inc. 1.74% 15,062,498 $37.2M No change
MAZE Maze Therapeutics Inc. 1.39% 2,412,471 $29.6M No change
OSCR Oscar Health Inc. Class A 0.48% 481,988 $10.3M No change
SANA Sana Biotechnology Inc. 0.36% 2,812,500 $7.7M No change
GLUE Monte Rosa Therapeutics Inc. 0.31% 1,464,015 $6.6M No change
VERA Vera Therapeutics Inc. 0.27% 241,264 $5.7M No change
BEAM Beam Therapeutics Inc. 0.26% 321,604 $5.5M No change
RLAY Relay Therapeutics Inc. 0.25% 1,568,753 $5.4M No change
DNTH Dianthus Therapeutics Inc. 0.18% 208,697 $3.9M No change
LYEL Lyell Immunopharma Inc. 0.12% 293,256 $2.6M No change
SPRO Spero Therapeutics Inc. 0.12% 889,979 $2.6M No change
FHTX Foghorn Therapeutics Inc. 0.11% 500,901 $2.4M No change
WGS Genedx Holdings Corp. 0.10% 22,711 $2.1M No change
AUTL Autolus Therapeutics PLC 0.07% 698,262 $1.6M No change
TCRX Tscan Therapeutics Inc. 0.07% 1,077,080 $1.6M No change
TSHA Taysha Gene Therapies Inc. 0.07% 640,882 $1.5M No change
BRNS Barinthus Biotherapeutics PL 0.07% 1,513,644 $1.4M No change
EXAS Exact Sciences Corp. 0.06% 23,205 $1.2M No change
GUTS Fractyl Health Inc. 0.05% 662,584 $1.1M No change
HYPR Hyperfine Inc. 0.03% 898,720 $647K No change
TNYA Tenaya Therapeutics Inc. 0.03% 915,705 $559K No change
QUINCE THERAPEUTICS INC 0.01% 189,122 $312K No change
ALEC Alector Inc. 0.01% 175,866 $246K No change
FULC Fulcrum Therapeutics Inc. 0.00% 14,262 $98K No change
RGEN Repligen Corp. 0.00% 383 $48K No change

Portfolio Sells Q1 2025 → Q2 2025
CRWD CrowdStrike Holdings Inc. Class A Sold out 0.00% −1.66
DM Desktop Metal Inc. Class A Sold out 0.00% −0.34
KRON Kronos Bio Inc. Sold out 0.00% −0.08
RANI Rani Therapeutics Holdings Class A Sold out 0.00% −0.04
VERV Verve Therapeutics Inc. Reduce -1.5% 6.40% +2.82

Portfolio Buys Q1 2025 → Q2 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 28$99.1BSPCX, PL, ASTS, CME, ARM
Q1 2026 26$4.0BCME, PL, ASTS, RVMD, ARM
Q4 2025 29$2.6BASTS, PL, RVMD, ARM, FRSH
Q3 2025 37$2.4BASTS, PL, ARM, MTSR, RVMD
Q2 2025 36$2.1BASTS, ARM, FRSH, PL, RVMD
Q1 2025 40$1.6BFRSH, ARM, ASTS, RVMD, MTSR
Q4 2024 40$1.7BGTLB, FRSH, ARM, RVMD, CRWD
Q3 2024 42$1.8BGTLB, ARM, RVMD, FRSH, CRWD
Q2 2024 42$2.0BGTLB, ARM, RVMD, CRWD, FRSH
Q1 2024 43$2.5BGTLB, CRWD, DXCM, ARM, FRSH